3.13
price up icon25.70%   0.64
after-market Handel nachbörslich: 3.24 0.11 +3.51%
loading
Schlusskurs vom Vortag:
$2.49
Offen:
$2.78
24-Stunden-Volumen:
49.01M
Relative Volume:
3.26
Marktkapitalisierung:
$1.05B
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-440.22M
KGV:
-1.8743
EPS:
-1.67
Netto-Cashflow:
$-400.48M
1W Leistung:
+61.34%
1M Leistung:
+58.08%
6M Leistung:
-47.75%
1J Leistung:
-62.42%
1-Tages-Spanne:
Value
$2.66
$3.175
1-Wochen-Bereich:
Value
$1.92
$3.175
52-Wochen-Spanne:
Value
$1.6385
$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Firmenname
Iovance Biotherapeutics Inc
Name
Telefon
(650) 260-7120
Name
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Mitarbeiter
838
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
IOVA's Discussions on Twitter

Vergleichen Sie IOVA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IOVA
Iovance Biotherapeutics Inc
3.13 647.83M 32.77M -440.22M -400.48M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-15 Herabstufung Goldman Neutral → Sell
2025-05-16 Herabstufung UBS Buy → Neutral
2025-05-12 Herabstufung Truist Buy → Hold
2025-05-09 Herabstufung Citizens JMP Mkt Outperform → Mkt Perform
2024-10-24 Eingeleitet UBS Buy
2024-07-29 Herabstufung Piper Sandler Overweight → Neutral
2023-11-20 Eingeleitet Goldman Buy
2023-09-18 Bestätigt Barclays Overweight
2023-05-30 Hochstufung Wells Fargo Equal Weight → Overweight
2023-03-27 Fortgesetzt Wells Fargo Equal Weight
2023-01-27 Hochstufung Piper Sandler Neutral → Overweight
2022-12-09 Herabstufung Goldman Buy → Neutral
2022-10-31 Eingeleitet Guggenheim Neutral
2022-08-18 Fortgesetzt Wells Fargo Equal Weight
2022-01-28 Hochstufung Stifel Hold → Buy
2021-12-07 Fortgesetzt Cowen Outperform
2021-06-10 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2021-05-20 Herabstufung Piper Sandler Overweight → Neutral
2021-05-19 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2021-05-19 Herabstufung Stifel Buy → Hold
2021-05-03 Eingeleitet Truist Buy
2021-04-16 Eingeleitet Goldman Buy
2021-03-08 Hochstufung H.C. Wainwright Neutral → Buy
2020-12-15 Herabstufung H.C. Wainwright Buy → Neutral
2020-10-06 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-22 Eingeleitet Mizuho Buy
2020-03-04 Eingeleitet Barclays Overweight
2020-02-26 Bestätigt H.C. Wainwright Buy
2020-02-26 Bestätigt Oppenheimer Outperform
2019-12-18 Eingeleitet JMP Securities Mkt Outperform
2019-10-01 Eingeleitet Stifel Buy
2019-04-29 Eingeleitet Piper Jaffray Overweight
2019-02-28 Bestätigt Chardan Capital Markets Buy
2019-02-07 Eingeleitet Robert W. Baird Outperform
2018-12-31 Fortgesetzt B. Riley FBR Buy
2018-07-06 Bestätigt Chardan Capital Markets Buy
2018-04-10 Hochstufung B. Riley FBR, Inc. Neutral → Buy
2018-03-13 Bestätigt B. Riley FBR, Inc. Neutral
2018-02-23 Herabstufung B. Riley FBR, Inc. Buy → Neutral
2018-01-25 Bestätigt H.C. Wainwright Buy
2017-11-01 Bestätigt B. Riley FBR, Inc. Buy
Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

pulisher
Jul 22, 2025

Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha

Jul 22, 2025
pulisher
Jul 22, 2025

Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Evaxion Biotech, Inxmed, Aivita Biomedical, Iovance Biotherapeutics, Viralyt - MenaFN

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st

Jul 22, 2025
pulisher
Jul 21, 2025

Iovance Biotherapeutics Inc Inc. (IOVA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com

Jul 21, 2025
pulisher
Jul 21, 2025

Is Iovance Biotherapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com

Jul 21, 2025
pulisher
Jul 21, 2025

This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside - Yahoo Finance

Jul 21, 2025
pulisher
Jul 20, 2025

Iovance Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - printweek.in

Jul 20, 2025
pulisher
Jul 20, 2025

Zacks Research Issues Pessimistic Estimate for IOVA Earnings - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

What drives Iovance Biotherapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

What analysts say about Iovance Biotherapeutics Inc. stockFree Stock Selection - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World

Jul 18, 2025
pulisher
Jul 17, 2025

Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid potential - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Iovance BioTherapeutics Sees Positive Trends with New Appointments and Promising Cancer Study - StocksToTrade

Jul 17, 2025
pulisher
Jul 16, 2025

Iovance Biotherapeutics Appoints New Chief Financial Officer - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics: Legal Woes Shake Investor Confidence - timothysykes.com

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Faces Legal Hurdles Amid Investor Concerns - StocksToTrade

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics, Inc. Appoints Corleen Roche as Chief Financial Officer, Effective August 6, 2025 - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionMulti Bagger Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Names Corleen Roche as Chief Financial Officer - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Citizens JMP reiterates Market Perform rating on Iovance stock By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Cambridge Investment Research Advisors Inc. Acquires 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Jul 15, 2025
pulisher
Jul 15, 2025

Amtagvi shows 61% response rate in less heavily treated melanoma patients - Investing.com Australia

Jul 15, 2025
pulisher
Jul 14, 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025 - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Levi & Korsinsky Reminds Iovance Investors of the Pending - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - The Globe and Mail

Jul 14, 2025
pulisher
Jul 14, 2025

IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

The Iovance Biotherapeutics Lawsuit: A Cautionary Tale of Investor Protection and Timely Legal Action - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Iovance Biotherapeutics Reports 61% Response Rate for Amtagvi® in Third-Line Melanoma Patients - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

New Real-World Data: Iovance's Melanoma Drug Amtagvi Achieves Breakthrough 61% Response Rate - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire

Jul 14, 2025
pulisher
Jul 14, 2025

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

July 14, 2025 Deadline: Join Class Action Lawsuit Against Iovance Biotherapeutics, Inc. (IOVA)Contact Levi & Korsinsky - ACCESS Newswire

Jul 14, 2025
pulisher
Jul 13, 2025

Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA) InvestorsContact Levi & Korsinsky Before July 14, 2025 - ACCESS Newswire

Jul 13, 2025
pulisher
Jul 13, 2025

IOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve

Jul 13, 2025

Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):